⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PFE News
Pfizer Inc.
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
prnewswire.com
PFE
ABBV
RMD
GSK
AZN
BNTX
INCY
IOVA
RGEN
MRK
LLY
IBIO
GILD
AMGN
JNJ
NVS
RIGL
BIIB
Knoa Pharma Board Appoints Michael Goettler as President and Chief Executive Officer
prnewswire.com
PFE
SNY
Blood Cancer United Welcomes New Board Members & Philanthropy Leadership
prnewswire.com
VVV
BIIB
BMY
GILD
MRK
PFE
AMGN
REGN
JNJ
ABBV
LULU
CGC
CRON
ACB
TLRY
SNDL
CVS
UNH
CI
CNC
HCA
THC
AI
NVDA
MSFT
GOOG
IBM
ORCL
AMD
INTC
QCOM
AMAT
MU
SMCI
ADSK
CBRE
JLL
SPG
PLD
EQIX
AMT
DigiCert Introduces Quantum Central to Help Organizations Prepare for Post-Quantum Cryptography
globenewswire.com
MSFT
GOOG
AMZN
IBM
ORCL
CSCO
NVDA
INTC
AMD
QCOM
AMAT
MU
ADBE
CRM
ACN
T
VZ
CMCSA
NFLX
DIS
BA
GD
LMT
RTX
HON
GE
CAT
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
PYPL
KO
PEP
MCD
SBUX
COST
WMT
HD
UNH
JNJ
PFE
MRK
ABBV
BMY
LLY
GILD
AMGN
BIIB
REGN
VRTX
GNTX
CTAS
PAYX
ADP
LRCX
KLAC
NXPI
MRVL
SNPS
CDNS
MCHP
ON
ADI
TXN
QGEN
ILMN
MDT
SYK
ISRG
ALGN
EW
TMO
DHR
GOOGL
AAPL
META
TSLA
100 Black Men of America Celebrated 40 Years of National Impact at Landmark Conference in New York City
prnewswire.com
KO
WFC
UPS
LLY
PFE
MSCI
WMT
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
globenewswire.com
MRNA
NUVL
PFE
LLY
NVS
Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair
businesswire.com
ULTA
CRSP
GILD
PFE
NVS
REGN
UCB
LLY
BIIB
ARCL
Xeal Launches In Canada On Canada Day, Bringing Self-Reliant EV Charging Technology To Canadian Properties
globenewswire.com
AVB
PFE
$960 Billion Proteins & Protein Crystals Market Outlook, 2030 | High Investment and Funding in Structural Biology, Biopharmaceuticals, and Advanced Drug Development
globenewswire.com
DHR
TMO
IFF
AMGN
LLY
PFE
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
globenewswire.com
PFE